Bioventus Inc. (NASDAQ:BVS – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $16.60.
A number of research analysts have weighed in on BVS shares. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price target on shares of Bioventus in a research note on Monday, August 17th. Weiss Ratings downgraded Bioventus from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. Craig Hallum reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Bioventus in a research report on Thursday, August 6th. Canaccord Genuity Group dropped their target price on Bioventus from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, November 3rd. Finally, Barrington Research set a $18.00 target price on Bioventus in a research report on Thursday, August 6th.
Check Out Our Latest Report on Bioventus
Institutional Investors Weigh In On Bioventus
Bioventus Price Performance
Shares of NASDAQ:BVS opened at $9.88 on Tuesday. Bioventus has a 52 week low of $6.47 and a 52 week high of $15.89. The company has a 50-day moving average price of $12.81 and a 200 day moving average price of $11.10. The company has a market cap of $832.49 million, a P/E ratio of 12.35, a PEG ratio of 1.27 and a beta of 0.66. The company has a quick ratio of 1.16, a current ratio of 1.68 and a debt-to-equity ratio of 0.72.
Bioventus (NASDAQ:BVS – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The company reported $0.17 EPS for the quarter, meeting the consensus estimate of $0.17. Bioventus had a net margin of 9.78% and a return on equity of 26.31%. The firm had revenue of $142.44 million during the quarter. Research analysts predict that Bioventus will post 0.78 earnings per share for the current year.
About Bioventus
Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew.
Featured Articles
- Five stocks we like better than Bioventus
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
